Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Date:5/2/2013

NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL).

A pre-recorded webcast featuring management from Janssen will provide an overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the investigational protease inhibitor simeprevir (TMC435) administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

 

 


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
2. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
3. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
4. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
5. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
6. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
7. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
8. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
9. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
10. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
11. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... Jan. 2 Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... Officer, will present a corporate update at the 26th ... January 7,2008 at 11:30 am (Pacific Standard Time) at ... be webcast live and may be accessed by visiting,Amicus, ...
... Inc. (Nasdaq: ALTH ) today announced that ... pre-specified 65-patient,safety review of data from the Company,s ... patients with relapsed or refractory peripheral,T-cell lymphoma (PTCL), ... the,protocol. This interim assessment was based upon an ...
Cached Medicine Technology:Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 2Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
(Date:11/23/2014)... Washington, DC (PRWEB) November 23, 2014 ... monthly Tech Report , which features the latest ... a technology expert and reporter for NewsWatch, conducted the ... cameras are unique and powerful options in the car ... is rising and it can be hard to find ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, ... attire in order to prepare for the wedding season. ... 70% off. , UWDress.com is a reliable company that ... especially the new items -- formal wedding guest attire. This ... market, including superstar and princess. As one of the leading ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to Attend Conference, LAS VEGAS, Sept. 10 ... http://www.skinvisible.com ), the developers,of Invisicare(R), a proprietary ... announced that Mr. Terry Howlett,President & CEO, will ... & Co.,Investor Summit on September 18, 2007 at ...
... Montague and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker ... of Massachusetts has,granted final approval of a $52.5 ... actions against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... a protein best known as a common marker of inflammation ... The research, published by Cell Press in the September issue ... a potential target for cancer treatment. , CRP is a ... during the process of inflammation in response to the inflammatory ...
... eating fattening foods and not getting enough exercise are all ... disease more so if you have a family history. ... women dont change these habits as often as men, even ... reporting in the September issue of the American Heart ...
... Expansion of Services Now Ranges From Birth Through ... The Exceptional,Children,s Foundation (ECF) announced today that it ... one of California,s largest and most,unique nonprofit organizations ... disabilities. As a result of the,merger, ECF becomes ...
... Abbott (NYSE:,ABT) -- the global health care company ... Index and the Dow Jones Sustainability North America,Index ... Abbott,s,continued leadership in business, environmental and social performance. ... approach to business," said,Miles D. White, chairman and ...
Cached Medicine News:Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2
... Available As One Unit, Shaped Like A Fan, ... Of A Phaco Incision. The Gauges Start At ... Up To With 100-Micron Increments. The ... Information As To The Preoperative And Postoperative Incision ...
... Unique Reversible Speculums Designed To ... By Flipping The Speculums Over, Allowing ... Palpebral Fissures To The Widest Possible ... Providing Unobstructed Around-The-Clock Access To The ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: